Human insulin ( DrugBank: Human insulin )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
96クローン病2
156レット症候群1

96. クローン病


臨床試験数 : 2,400 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 168 - 標的パスウェイ数 : 214
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022215-19-GB
(EUCTR)
21/07/201123/06/2011Combined growth hormone and IGF1 therapy in paediatric Crohn'd diseaseA Pharmacokinetic Study Of The Combined Use Of Recombinant Human GH And IGF-1 In Children With Inflammatory Bowel (Crohn’s) Disease - Combination rhGH + rhIGF-1 in childhood/adolescent Crohn’s Impaired growth in Paediatric Crohn's disease
MedDRA version: 14.1;Level: LLT;Classification code 10011398;Term: Crohn's;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Increlex
Product Name: Increlex 10mg/ml solution for injection
INN or Proposed INN: Mecasermin [rDNA Origin] 10mg/ml solution
Other descriptive name: Recombinant human Insulin-like Growth Factor
Trade Name: NutropinAq®
Product Name: NutropinAq 10mg/2ml solution for injection
INN or Proposed INN: Somatropin(rhGH)
Other descriptive name: recombinant growth hormone
Greater Glasgow & Clyde NHSNULLNot RecruitingFemale: yes
Male: yes
24Phase 2United Kingdom
2EUCTR2007-004269-16-GB
(EUCTR)
28/02/200826/03/2008Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I) in children with Crohn’s disease-induced growth retardation. - IGF-I in growth-retarded Crohn's disease childrenPharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I) in children with Crohn’s disease-induced growth retardation. - IGF-I in growth-retarded Crohn's disease children Growth failure in children with Crohn's diseaseTrade Name: Increlex
Product Name: Increlex 10mg/ml solution for injection
Queen Mary, University of LondonNULLNot RecruitingFemale: yes
Male: yes
United Kingdom

156. レット症候群


臨床試験数 : 40 薬物数 : 53 - (DrugBank : 19) / 標的遺伝子数 : 77 - 標的パスウェイ数 : 113
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01777542
(ClinicalTrials.gov)
January 201323/1/2013Treatment of Rett Syndrome With Recombinant Human IGF-1Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)Rett SyndromeDrug: Recombinant Human Insulin Growth Factor 1 (rhIGF-1);Drug: PlaceboBoston Children's HospitalInternational Rett Syndrome FoundationCompleted2 Years10 YearsFemale30Phase 2United States